These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
785 related articles for article (PubMed ID: 17443605)
1. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605 [TBL] [Abstract][Full Text] [Related]
2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419 [TBL] [Abstract][Full Text] [Related]
3. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus. Hemmingsen B; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147 [TBL] [Abstract][Full Text] [Related]
4. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668 [TBL] [Abstract][Full Text] [Related]
5. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405 [TBL] [Abstract][Full Text] [Related]
6. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543 [TBL] [Abstract][Full Text] [Related]
7. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Monami M; Marchionni N; Mannucci E Diabetes Obes Metab; 2009 Apr; 11(4):372-8. PubMed ID: 19267715 [TBL] [Abstract][Full Text] [Related]
8. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Warren E; Weatherley-Jones E; Chilcott J; Beverley C Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study. Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837 [TBL] [Abstract][Full Text] [Related]
10. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Dejgaard A; Lynggaard H; Råstam J; Krogsgaard Thomsen M Diabetologia; 2009 Dec; 52(12):2507-12. PubMed ID: 19838665 [TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. Duckworth W; Davis SN J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554 [TBL] [Abstract][Full Text] [Related]
12. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin. Dailey GE; Gao L; Aurand L; Garg SK Diabetes Obes Metab; 2013 Dec; 15(12):1085-92. PubMed ID: 23683002 [TBL] [Abstract][Full Text] [Related]
13. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Frier BM; Russell-Jones D; Heise T Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900 [TBL] [Abstract][Full Text] [Related]
14. Insulin glargine: a systematic review of a long-acting insulin analogue. Wang F; Carabino JM; Vergara CM Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485 [TBL] [Abstract][Full Text] [Related]
15. Differences between long-acting insulins for the treatment of type 2 diabetes. Jensen MG; Hansen M; Brock B; Rungby J Expert Opin Pharmacother; 2010 Aug; 11(12):2027-35. PubMed ID: 20642370 [TBL] [Abstract][Full Text] [Related]
16. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Valentine WJ; Goodall G; Aagren M; Nielsen S; Palmer AJ; Erny-Albrecht K Adv Ther; 2008 Jun; 25(6):567-84. PubMed ID: 18568451 [TBL] [Abstract][Full Text] [Related]
17. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040 [TBL] [Abstract][Full Text] [Related]
18. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine. Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113 [TBL] [Abstract][Full Text] [Related]
19. Insulin detemir: a review of its use in the management of diabetes mellitus. Keating GM Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609 [TBL] [Abstract][Full Text] [Related]
20. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Monami M; Marchionni N; Mannucci E Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]